Cohort Study

Clinical outcomes and costs of the use of fibrin sealant in pancreaticojejunal anastomosis after pancreaticoduodenectomy: a retrospective analysis study

Alberto Facury Gaspar a,∗, Rafael Kemp b, Ajith Kumar Sankaran Kutty b, Jorge Resende Lopes Júnior a, João Almiro Ferreira Filho a, Daniel Martone a, Gustavo de Assis Mota a, José Sebastião dos Santos b

a Hospital das Clínicas, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
b Division of Gastrointestinal Surgery, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil

ARTICLE INFO

Keywords:
Pancreaticoduodenectomy
Fibrin sealant
Pancreatic fistula
Healthcare costs

ABSTRACT

Objectives: The benefits of using a fibrin sealant to reinforce the pancreaticojejunal anastomosis are still contentious, a fact that justifies the study of its effects on clinical outcomes and costs of pancreaticoduodenectomy.

Methods: Study of 62 consecutive patients submitted to pancreaticoduodenectomy, divided into two groups of 31 patients each: GWS = group with sealant and GWOS = group without sealant that were compared according to demographic, clinical, laboratory aspects, the incidence of postoperative pancreatic fistula (POPF), according to the definition of the International Study Group on Pancreatic Fistula, updated in 2016, and its postoperative complications categorized according to the Clavien classification, as well as hospital costs evaluated by the absorption costing method (with the exception of those related to medications).

Results: The groups were homogeneous and there were no significant differences in the postoperative clinical course or in the indicators of hospital care between them. Hard texture of pancreatic tissue was the only protective factor against the development of POPF (RR = 0.29 (95%CI:0.12–0.68); p = 0.005). Moreover, hospital costs were higher in GWS than in GWOS (p < 0.0001).

Conclusions: The use of fibrin sealant to reinforce pancreaticojejunal anastomosis did not improve the clinical and healthcare outcomes and, in addition, increased hospital costs.

1. Introduction

Pancreaticoduodenectomy is the treatment of choice for resectable tumors of the pancreato-duodenal confluence, but despite the decline in mortality rates to approximately 5% over the years, morbidity rates remain high ranging between 30% and 50% [1]. The most frequent complications from the procedure are attributed to pancreatic fistula which is associated with delayed gastric emptying, postoperative bleeding, and complications after arterial reconstruction [2].

Pancreatic fistula is the most feared post pancreatic surgery complication and its occurrence increases the length of hospital stay and treatment costs, requires additional investigations and procedures, and may result in further complications such as abdominal collections and sepsis [3]. The reported incidence of pancreatic fistula in patients submitted to pancreaticoduodenectomy differs among studies, varying between 5% and 35% [4].

Several alternatives have been used in an attempt to decrease the incidence of pancreatic fistula including the administration of octreotide [5], alternative techniques of pancreatico-jejunoanostomy [6], stent placement in pancreatic duct [7], drain management [8], use of microscopy [9], and use of adhesives or fibrin sealants [10–13].

The fibrin sealant, produced in the laboratory in 1980 and sold in 1998, consists of an adhesive formed from the union of fibrinogen and thrombin, with the principle of mimicking the last step of the human coagulation cascade. Despite several commercial formulations, the principle of use is the same, with different indications for its use, such as control of local hemostasis, sealing and adhesion of stapling lines and anastomoses, in addition to strengthening wound healing [11].

Studies on the effects of using fibrin sealant in pancreatic surgery are scarce and controversial. There is only one systematic review on the
topic [12] which reported a 35% incidence of pancreatic fistula and a trend of reduction in the incidence of postoperative bleeding and formation of postoperative intra-abdominal collections. Thus, the adoption of alternatives to reduce morbidity and mortality after pancreatic resection, namely in the contexts of clinical management [14–16], clinical care [17], and surgical technique [14,18], is pertinent. In this context, the scarcity of data on the effects of fibrin sealant used in pancreaticojejunostomy, the controversial results of the available studies, the lack of assessment of the costs incurred, and the claims of the pharmaceutical industry emphasizing its advantages warrant a detailed study on the effects of using fibrin sealant to reinforce pancreaticojejunal anastomosis on clinico-surgical outcomes and hospital costs.

2. Materials and methods

2.1. Study design, location, and data collection

The present study was a retrospective analysis, with uncontrolled intervention, based on a collection of data from medical records of 62 patients submitted to pancreaticoduodenectomy (with or without pylorus preservation), treated consecutively by the same team of surgeons between 2007 and 2012, regardless of the disease that prompted the procedure, divided into two groups of 31 patients each: GWS = group with sealant and GWOS = group without sealant.

The patients underwent surgery at the Hospital das Clínicas of the Ribeirão Preto Medical School, University of São Paulo (HCFMRP-USP), a tertiary public teaching hospital.

The data retrieved from active, semi-active, and death records and from the clinical and administrative data system of the hospital were registered in a data sheet created for the purpose of the present study, along with the demographic, clinical and morphological characteristics, preoperative assessment, perioperative care, surgical technique, anatomicopathological findings, postoperative complications, consumables, and costs. The work has been reported in line with the STROCSS criteria [19].

The study was approved by the ethics committee (CEP HCFMRP-USP, 723,520, July 21, 2014).

2.2. Reconstruction of the gastrointestinal tract

Pancreatectoduodenectomy was performed through a wide bilateral subcostal incision with resection of the pancreatic head, duodenum, gastric antrum (in cases without pylorus preservation), common extrahepatic bile duct, and gallbladder.

Tract reconstruction was performed in a single intestinal loop with three anastomoses. Pancreatecojejunostomy was performed in two layers: pancreatic capsule/jejunal serosa with interrupted, nonabsorbable polyester 2-0 suture, and pancreatic duct/jejunal mucosa using interrupted, polypropylene 5-0 suture. A transanastomotic internal plastic stent was placed with the exception of one case in each group for which telescoping of the pancreatic stump in the jejunal loop was performed because the main pancreatic duct was not identified. In these cases, the free pancreatic stump was invaginated into the jejunal lumen and fixed with nonabsorbable polyester 2-0 suture in two layers between the pancreatic capsule and the jejunal wall. The end-to-side bilio-jejunal anastomosis was performed in the same jejunal loop, approximately 10 cm from the pancreatic anastomosis in a single layer with continuous absorbable 4-0 suture. After approximation of ligaments and peritoneum which shape the duodenojejunal flexure, duodenoojejunal or transmesocolic end-to-side gastrojejunal anastomosis was performed approximately 15–20 cm distal to the bilio-jejunal anastomosis, in a single layer, with continuous nonabsorbable monofilament 3-0 or 4-0 suture, and was sutured in the inframesocolic space with interrupted stitches between the peritoneum and the stomach using the same type of thread.

2.3. Fibrin sealant

Fibrin sealant in pancreatic anastomosis was used by convenience and availability in the first four years (19 patients in GWOS, 61% of total; 7 patients in GWS, 22% of total) and subsequently randomly (like yes/no) until the two groups were formed. The size of the groups was adjusted according to the availability of the material (sealant fibrin) in our hospital.

It was always applied at the end of the procedure, after the removal of fluids around the anastomosis, and the volume varied between 1.5 mL and 7 mL (mean 3.55 mL). The following brands were used depending on availability: BERIPLAST (3 mL kit) (CSL Behring, Marburg - Germany) in 85% of the cases and TISSUCOL (0.5 mL kit) (Baxter AG, Viena, Austria) in 15% of the cases. All the elements in the package were assembled and the sealant was applied homogeneously to the entire pancreatic anastomosis on its anterior and posterior sides. A tubular silicone drain was placed in the supramesocolic space, anterior to the bilio-jejunal and pancreaticojejunal anastomoses, with its end behind the posterior wall of the stomach and exteriorized on the right side.

2.4. Pancreatic fistula and surgical complications

Pancreatic fistula was classified according to the universally accepted definition and revised in 2016 by the International Study Group on Pancreatic Fistula, in BL (Biochemical leak), B and C, and any drainage of cavity secretion used as a definition of pancreatic fistula beyond the 3rd day of postoperative, with the higher serum normal value, associated with any relevant clinical condition related to the fistula itself [20].

The postoperative complications were categorized based on the Clavien-Dindo classification [21,22].

2.5. Cost analysis

The micro-costing method was used to assess the costs of the procedures performed in the operating room, in the ward of the Digestive Surgery Division or in the intensive care unit. The cost accounting department of the HCFMRP-USP determined the costs of hospitalization, laboratory tests, and imaging exams during hospitalization using the absorption costing method with simple apportionment of all fixed expenses (e.g., staff, materials, technologies, water, electricity, telephone). Expenses with medications were accounted for separately. The costs of medications included all medications used during the hospitalization period and surgery costs included only the materials used during the procedure with fixed costs being excluded.

2.6. Statistical analysis

The groups were compared using the non-parametric Mann-Whitney test for quantitative analysis and Fisher’s exact test for comparative analysis, with a significance level of 5%. For multivariate analysis of predictors of risk for POPF, Poisson regression models with robust variance were fitted to the data, with POPF as the independent variable. The relative risks of each covariable were evaluated, with a confidence interval of 95%, and significance set at p < 0.05.

3. Results

The groups were homogeneous for the demographic, clinical, and perioperative care variables, among others, as shown in Table 1. The global incidence of POPF in both groups was 24% (n = 15/62). The histopathological findings were similar between the groups (Table 2).

There was a predominance of POPF graded as type B and C according to the ISGPS 2016 classification, instead of BL, but no significant difference was observed between the groups. Overall mortality was 4.8%
Grading of POPF (ISGPS 2016).

**Table 2**

Histopathological findings in the groups without (GWOS) and with (GWS) fibrin sealant.

|                              | GWOS (n = 31) | GWS (n = 31) |
|------------------------------|---------------|--------------|
| Pancreatic adenocarcinoma     | 12 (38.7%)    | 12 (38.7%)   |
| Adenocarcinoma of the papilla| 9 (29%)       | 12 (38.7%)   |
| Bile duct adenocarcinoma      | 3 (9.6%)      | 3 (9.6%)     |
| Duodenal adenocarcinoma       | 2 (6.5%)      | 2 (6.5%)     |
| Endocrine neoplasia           | 2 (6.5%)      | 2 (6.4%)     |
| Other                         | 3 (9.7%)      | 3 (9.6%)     |

**Table 3**

Grading of fistulas in the groups without (GWOS) and with (GWS) fibrin sealant.

| Classification of complications of pancreatic surgery (Clavien score) | GWOS (n = 31) | GWS (n = 31) | p    |
|-----------------------------------------------------------------------|---------------|--------------|------|
| Class I                                                               | 15 (48%)     | 17 (55%)     | 0.7997|
| Class II                                                              | 12 (38%)     | 11 (35%)     | 1    |
| Class III                                                             | 2 (7%)       | 1 (3.3%)     | 1    |
| Class IV                                                              | 0            | 0            | 1    |
| Class V                                                               | 0            | 0            | 1    |

**Table 4**

Risk predictors for postoperative pancreatic fistula in the groups without (GWOS) and with (GWS) fibrin sealant.

|                              | Adjusted RR | Confidence interval 95% | p value |
|------------------------------|-------------|-------------------------|---------|
| Use of fibrin sealant        | 1.05        | 0.42 - 2.60             | 0.921   |
| Age (>65 years)              | 1.01        | 0.38 - 2.67             | 0.980   |
| Albumin (<3.5 mg/dL)         | 1.39        | 0.56 - 3.44             | 0.474   |
| Preoperative biliary decompression | 0.86   | 0.32 - 2.26             | 0.754   |
| Texture of the pancreas (hard) | 0.29    | 0.12 - 0.68             | 0.005   |
| Pancreatic duct diameter (<3 mm) | 2.06   | 0.86 - 4.95             | 0.104   |
| Duration of surgery (>480 min) | 1.39     | 0.63 - 3.09             | 0.413   |
| Antibiotic (prophylaxis)     | 2.12        | 0.82 - 5.47             | 0.121   |
| Bile culture (Positive)      | 0.84        | 0.47 - 1.50             | 0.550   |

There was no significant difference in the costs of hospitalization, medications, laboratory tests, and imaging exams in the postoperative period until discharge. The cost of the surgical procedure in GWS was higher than that in GWOS (Table 5).

**4. Discussion**

Topical application of fibrin with the aim of improving local hemostasis and healing has been practiced for over a century [23]. Although there is a vast literature on the use of fibrin sealant in various areas of surgery, including orthopedic [24], cardiac [25], and hepatic [26] surgery, its use in pancreatic surgery remains controversial and literature on the topic is scarce [13].

There is only one systematic review with a metaanalysis [12] that included 897 patients submitted to pancreatic surgery (pancreaticoduodenectomy and body-tail or left pancreatectomy), with seven randomized controlled studies in which it was concluded that the fibrin sealant did not affect the incidence of POPF or its complications, but requires further investigations.

A recent randomized multicenter study assessed the effects of fibrin sealant on 142 patients submitted to pancreaticoduodenectomy, with each group containing 71 patients. The analyzed variables, including incidence and severity of POPF showed no significant difference [27].

Although the groups assessed in the present study weren’t randomly formed, all patients were treated under similar care conditions and using similar clinical-surgical protocols. The demographic, epidemiological, clinical, and morphological characteristics and the preoperative laboratory findings were also homogenous among the groups. Some aspects related to the characteristics of the study location such as duration of surgery, length of hospital stay and abdominal drain dwell time were also not significantly different between the study groups.

The histopathological findings were similar between the groups. Frequency results were in line with the literature, with a predominance of pancreatic head adenocarcinoma [28]. The incidence of POPF, which was 24%, did not differ between groups, and was very similar to the findings reported in the literature [29]. This indicated that the use of fibrin sealant did not prevent the occurrence of POPF.

In addition, fibrin sealant did not alter the severity of pancreatic POPF, post-operative pancreatic fistula.

(Table 3)

Multivariate analysis showed that hard consistency of pancreatic tissue was an independent predictor of protection against the occurrence of POPF (RR = 0.29 (95% CI 0.12-0.68); p = 0.005) (Table 4).

There was no significant difference in the costs of hospitalization, medications, laboratory tests, and imaging exams in the postoperative period until discharge. The cost of the surgical procedure in GWS was higher than that in GWOS (Table 5).
Ethical approval
Junior - contributor, Ajith Kumar Sankarankutty - contributor, Joao Artur Facury Gaspar - contributor, Joao Almiro Ferreira Filho - contributor, Daniel Martone - contributor, Aldeberto Facury Gaspar - contributor, Joao Siqueira dos Santos.

Provenance and peer review
Not commissioned, externally peer-reviewed.

Guanantor
Alberto Facury Gaspar.
José Sebastião dos Santos.

Declaration of competing interest
No conflicts of interest.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.amss.2021.102531.

References
[1] J.M. Winter, J.L. Cameron, K.A. Campbell, et al., 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience, J. Gastrointest. Surg. 10 (9) (2006) 1199–1210.
[2] L. Fernández-Cruz, I. Sabater, J. Fabregat, et al., Complications after pancreaticoduodenectomy, Cir. Esp. 90 (4) (2012) 222–232.
[3] W.B. Pratt, S.K. Matthei, T. Vamouou, et al., Clinical and economic validation of the international study group of pancreatic fistula (ISGPF) classification scheme, Ann. Surg. 245 (3) (2007) 443–451.
[4] K.S. Gurumsamy, R. Kotti, G. Fustai, et al., Somatostatin analogues for pancreatic surgery, Cochrane Database Syst. Rev. 6 (2012).
[5] C.J. Yeo, J.L. Cameron, K.D. Lillemoe, et al., The prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial, Ann. Surg. 232 (3) (2000) 419–429.
[6] C. Bassi, M. Falconi, E. Molinari, et al., Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial, Surgery 134 (5) (2003) 766–771.
[7] J.M. Winter, J.L. Cameron, K.A. Campbell, et al., Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial, J. Gastrointest. Surg. 10 (9) (2006) 1280–1290.
[8] M. Kawai, M. Tanii, H. Terasawa, et al., Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for 104 consecutive patients, Ann. Surg. 244 (1) (2006) 1.
[9] K. Wada, L.W. Traverso, Pancreatic anastomotic leak after the Whipple procedure is reduced using the surgical microscope, Surgery 139 (6) (2006) 735–742.
[10] K.D. Lillemoe, J.L. Cameron, M.P. Kim, et al., Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial, J. Gastrointest. Surg. 8 (7) (2004) 766–772.
[11] W.D. Sponzil, Fibrin sealant: past, present, and future: a brief review, World J. Surg. 34 (2010) 632–634.
[12] L.A. Orci, G. Oldani, T. Berney, et al., Systematic review and meta-analysis of fibrin sealants for patients undergoing pancreatic resection, HPB 16 (1) (2014) 3.
[13] J. Gong, S. He, Y. Cheng, et al., Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery (Review), Cochrane Database Syst. Rev. 6 (2018), https://doi.org/10.1002/14651858.CD009621.
[14] J.S. Santos, E.D. Mente, A.K. Sankarankutty, et al., Avaliação Instrumental de Evolução de Morbidade e Mortalidade após Antroduodenopancreatpectomia Cefálica, Rev. Col. Bras. Cir. 26 (1999) 17–20.
[15] T.S. Riall, K.A. Eschbach, C.M. Townsend, et al., Trends and disparities in regionalization of pancreatic resection, J. Gastrointest. Surg. 11 (10) (2007) 1242–1251.
[16] J.S. Santos, R. Kemp, Sankarankutty, et al., Clinical and regulatory protocol for the treatment of jaundice in adults and elderly subjects: a support for the health care network and regulatory system, Acta Cir. Bras. 23 (2008) 133–142.
[17] J.S. Don Santos, W.S. Júnior, J.L. Modena, et al., Effect of preoperative endoscopic decompression on malignant biliary obstruction and postoperative infection, Hepato-Gastroenterology 52 (61) (2005) 45–47.
[18] C.K. Munia, J.S. dos Santos, K. Prümer, et al., Nutritional status, fecal elastase-1, and 13C-labeled mixed triglyceride breath test in the long-term after pancreaticoduodenectomy, Pancreas 43 (3) (2014) 445–450.
[19] R. Agba, A. Abdall-Razak, E. Crossley, N. Dowlut, G. Mathew, for the STROCSS Group, The STROCSS 2019 guidelines: strengthening the reporting of cohort studies in surgery, Int. J. Surg. 72 (2019) 156–165.
[20] C. Bassi, G. Marchegiani, C. Derervis, et al., The 2016 update of the International Study Group (ISGPF) definition and grading of postoperative pancreatic fistula: 11 years after, Surgery 161 (3) (2017) 584–591.
[21] M.L. DeOliveira, J.M. Winter, M. Schafer, et al., Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy, Ann. Surg. 244 (6) (2006) 931–937.
[22] D. Dindo, N. Demartines, P.A. Clavien, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann. Surg. 240 (2) (2004) 205–213.
[23] S. Bergel, Uber wirkungen des fibrins, Dtsch. Med. Wochenschr. 35 (1909) 633–665.

Author contribution
Alberto Facury Gaspar - study design, data collections, writing, José Sebastião dos Santos - writing, study design, revisor, Rafael Kemp - contributor, João Almiro Ferreira Filho - contributor, Daniel Martone - contributor, Gustavo de Assis Mota - contributor, Jorge Resende Lopes Junior - contributor, Ajith Kumar Sankarankutty - contributor.

Research registration
Name of the registry: Clinical outcomes and costs of the use of Fibrin Glue in Pancreatic Surgery.
Unique identifying number or registration ID: RBR-10t84b5s
Hyperlink to your specific registration (must be publicly accessible and will be checked):
Brazilian Clinical Trials Registry (ReBec).
https://ensaiosclnicos.gov.br/rg/RBR-10t84b5s.
[24] O. Levy, U. Martinowitz, A. Oran, et al., The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective, randomized, multicenter study, J Bone Joint Surg Am 81 (11) (1999) 1580–1588.

[25] J. Lowe, J. Luber, S. Levitsky, et al., Evaluation of the topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with currently licensed TISSEEL VH in patients undergoing cardiac surgery; a phase 3, randomized, double-blind clinical study, J. Cardiovasc. Surg. 48 (3) (2007) 323–331.

[26] M.T. de Boer, E.A. Boonstra, T. Lisman, et al., Role of fibrin sealants in liver surgery, Dig. Surg. 29 (1) (2012) 54–61.

[27] M. Schindl, R. Függer, P. Götzinger, et al., Effects of fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy, BJS 105 (2018) 811–819.

[28] G. Conzo, C. Gambardella, E. Tartaglia, et al., Pancreatic fistula following pancreatoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review, Int. J. Surg. 21 (2015) 54–59.

[29] Pancreatic Section BiSoG, Ireland PsSoGBa, Ireland AoUGSoGBa, Pathologists RCo, Radiology SIGfG-I, Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas, Gut 54 (5) (2005) 1–14.

[30] D. Fuke, G. Piessen, E. Huet, et al., Life-threatening postoperative pancreatic fistula (grade C) after pancreatoduodenectomy: incidence, prognosis, and risk factors, Am. J. Surg. 197 (6) (2009) 702–709.

[31] I. Martin, K. An, Does fibrin glue sealant decrease the rate of anastomotic leak after a pancreatoduodenectomy? Results of a prospective randomized trial, HPB 15 (8) (2013) 561–566.

[32] S.V. Shrikhande, M.A. D’Souza, Pancreatic fistula after pancreatectomy: evolving definitions, preventive strategies and modern management, World J. Gastroenterol. 14 (38) (2008) 5789–5796.